Impact of the levonorgestrel-releasing intrauterine device on controlled ovarian stimulation outcomes

Levonorgestrel-releasing intrauterine device can be used in oocyte donors during ovarian stimulation.

Seven oocyte donors with a levonorgestrel-releasing intrauterine device (LNG-IUD) in situ (group A) underwent ovarian stimulation with human menopausal gonadotrophin (HMG) after goserelin down-regulation, in eight treatment cycles. The donors in a control group (group B, n = 16) were comparable in age, body mass index and parity characteristics. There were no statistically significant differenc...

Hypertension and use of an intrauterine levonorgestrel-releasing device.

Levonorgestrel-Releasing Intrauterine Device-Related Acute Liver Injury

Oral contraceptives have long been associated with liver injury. However, very little attention is paid to the metabolic side effects of hormone-releasing intrauterine devices (IUDs). These devices are generally considered safe and commonly used. We report for the first time acute liver injury associated with a levonorgestrel-releasing IUD. Our patient did not have any comorbidities that could ...

TCRM_5624_The levonorgestrel-releasing intrauterine system

Correspondence: Paul D Blumenthal Department of Obstetrics and Gynecology, 300 Pasteur Drive, Stanford University Hospital, C/O Office of Obstetrics and Gynecology, Stanford, CA 94305, USA email [email protected] Abstract: The levonorgestrel-releasing intrauterine system (LNG-IUS) is a safe, effective and acceptable form of contraception used by over 150 million women worldwide. It also has ...

The Effect of a Levonorgestrel-releasing Intrauterine Device on Ovariectomized Rat Endometrium under Estrogen Replacement Therapy

Objective: Our aim was to investigate the effects of levonorgestrel-releasing intrauterine system on the endometrium of ovariectomized rats under estrogen replacement therapy. Methods: Twenty-four Sprague-Dawley rats were divided into four groups and operated for the insertion of levonorgestrelreleasing (3 μg/day) or placebo-bearing intrauterine devices (IUD). Following the operation, the rats ...